Saniabadi A - Search Results

1

Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Muratov V, et al. Among authors: saniabadi a. Int J Colorectal Dis. 2006 Sep;21(6):493-504. doi: 10.1007/s00384-005-0069-2. Epub 2006 Mar 15. Int J Colorectal Dis. 2006. PMID: 16538495

2

Therapeutic leukocytapheresis for inflammatory bowel disease.

Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Saniabadi AR, et al. Transfus Apher Sci. 2007 Oct;37(2):191-200. doi: 10.1016/j.transci.2007.08.003. Epub 2007 Oct 31. Transfus Apher Sci. 2007. PMID: 17974479 Review.

3

Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes.

Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Saniabadi AR, et al. J Clin Apher. 2019 Feb;34(1):51-60. doi: 10.1002/jca.21670. Epub 2018 Nov 8. J Clin Apher. 2019. PMID: 30407662 Review.

4

A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis.

Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. Suzuki Y, et al. Dig Dis Sci. 2006 Nov;51(11):2031-8. doi: 10.1007/s10620-006-9199-9. Epub 2006 Sep 27. Dig Dis Sci. 2006. PMID: 17004123

5

Clinical response is associated with elevated plasma interleukin-1 receptor antagonist during selective granulocyte and monocyte apheresis in patients with ulcerative colitis.

Sakimura K, Omori T, Iwashita E, Yoshida T, Tsuzuki Y, Fujimori K, Konishi F, Yoshida Y, Anzai H, Suzuki H, Sugawara S, Takeda Y, Hiraishi K, Saniabadi AR, Ide T, Miura S, Ota S. Sakimura K, et al. Dig Dis Sci. 2006 Sep;51(9):1525-31. doi: 10.1007/s10620-005-9012-1. Epub 2006 Aug 12. Dig Dis Sci. 2006. PMID: 16902810 Clinical Trial.

6

Selective granulocyte and monocyte apheresis as a new adjunct to enhance the efficacy of interferon-alpha + ribavirin in patients with high plasma hepatitis C virus.

Sawada K, Kashiwamura S, Okamura H, Ohnishi K, Fukunaga K, Hirata I, Saniabadi A. Sawada K, et al. Among authors: saniabadi a. Dig Liver Dis. 2005 Jul;37(7):515-21. doi: 10.1016/j.dld.2005.01.014. Epub 2005 Apr 7. Dig Liver Dis. 2005. PMID: 15975539

7

Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings.

Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Yamamoto T, et al. Inflamm Bowel Dis. 2006 Aug;12(8):719-26. doi: 10.1097/00054725-200608000-00008. Inflamm Bowel Dis. 2006. PMID: 16917227

8

Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Saniabadi AR, et al. World J Gastroenterol. 2014 Aug 7;20(29):9699-715. doi: 10.3748/wjg.v20.i29.9699. World J Gastroenterol. 2014. PMID: 25110409 Free PMC article. Review.

9

Correlation of neutrophil and monocyte derived interleukin-1 receptor antagonist and interleukin-8 with colitis severity in the rabbit.

Kaneda K, Saitoh F, Shibusawa H, Maegawa H, Saniabadi AR, Kashiwagi N, Matsukawa A. Kaneda K, et al. Among authors: saniabadi ar. Cytokine. 2011 Nov;56(2):508-14. doi: 10.1016/j.cyto.2011.07.008. Epub 2011 Jul 31. Cytokine. 2011. PMID: 21807533

10

Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous.

Sawada K, Takahashi R, Saniabadi AR, Ohdo M, Shimoyama T. Sawada K, et al. World J Gastroenterol. 2006 Mar 14;12(10):1621-5. doi: 10.3748/wjg.v12.i10.1621. World J Gastroenterol. 2006. PMID: 16570358 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results